FDA tentatively OKs Perrigo's Sernivo Spray 0.05%

|About: Perrigo Company plc (PRGO)|By:, SA News Editor

The FDA tentatively approves Perrigo's (NYSE:PRGO) generic version of Sernivo (betamethasone dipropionate) Spray 0.05%. Perrigo previously settled its Sernivo patent dispute with Promius Pharma.

Tentative approval means that the application met the requirements for safety and efficacy but patent issues need to be resolved.

Per IQVIA, market sales for year ended February 2019 were ~$15M.

Previously: Perrigo settles Sernivo patent dispute with Promius (Nov. 28, 2018)

Subscribe for full text news in your inbox